More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016NORTH CHICAGO, Ill., Aug. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 2024-2025 recipients of the AbbVie Immunology Scholarship, aimed to support students living with chronic, inflammatory diseases as they pursue higher education.Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/9253951-abbvie-immuno ...

SkinMedica®, by the makers of BOTOX® Cosmetic (onabotulinumtoxinA) launches the first and only product to use a proprietary complex of five forms of Hyaluronic Acid (HA) and Hydra Collagen, plus Advanced VITISENSCE® Technology for deeper hydrationIRVINE, Calif., Aug. 27, 2024 /PRNewswire/ -- For 25 years, SkinMedica® has been at the forefront of science-based skincare solutions, and today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of its next generation hydration product: Ski ...

29 April 2024, Rhineland-Palatinate, Ludwigshafen: Photo: Uwe Anspach/dpa (Photo by Uwe ... [+] Anspach/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesWe believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap in valuation will narrow in favor of Merck in the coming years, given its superior revenue growth and profitability. There is more to the co ...

AbbVie (ABBV) and partner, Genmab (GMAB) , announced that the European Commission has granted conditional marketing authorization for the expanded use of Tepkinly (epcoritamab) to treat relapsed or refractory follicular lymphoma (FL) after two or more therapies. R/R FL is a particularly difficult-to-treat form of cancer, especially in later lines of therapy, for which there is currently no standard of care treatment.The encouraging regulatory update follows the positive opinion that was adopted by the advis ...

TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyFL is an incurable form of non-Hodgkin's lymphoma (NHL), with about 13,000 estimated cases in Western Europe alone each year1NORTH CHICAGO, Ill., Aug. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that ...

These stocks dividends continue to flow and grow.What do income investors like better than a stock that pays a juicy dividend yield? The answer is easy: A stock with a juicy dividend yield that's likely to grow its dividend payout over time.Such stocks aren't as hard to find as some might think. Here are three high-yield dividend stocks to buy now that have increased their dividends for 25 years or more.1. AbbVieAbbVie's (ABBV 0.26%) forward dividend yield of over 3.2% isn't as high as it was earlier this y ...

This list of top-selling drugs could look drastically different in a few years.You might think that if a drugmaker has a top-selling drug, it would be a lock to be a top-performing stock and a no-brainer buy. That may be true in some cases. In others, it can be a source of risk as investors grow concerned about what a company's growth opportunities will look like after the relevant patent expires, especially when the drug accounts for a significant chunk of the company's sales.The three top-selling drugs in ...

文章核心观点 - 文章介绍了3家具有高股息和持续增长股息的公司,包括制药公司AbbVie、电信公司Verizon和房地产投资信托公司Prologis [1][2][3] - 这些公司都具有良好的财务状况,能够为投资者提供稳定的股息收益,是退休投资者的理想选择 [2] AbbVie - AbbVie是一家制药公司,目前股息收益率为3.3%,高于标准普尔500指数的1.4% [4] - 公司在过去5年内将股息增加了45%,年复合增长率达7.7% [4] - 公司除了提供高股息,还有良好的增长前景,通过并购等方式来拓展业务 [5] - 公司面临专利到期的挑战,但预计明年将恢复强劲增长,长期目标为高单位数的复合增长率 [6] - 公司盈利稳定,股价估值合理,是一个全面的投资标的 [7] Verizon - Verizon是一家电信巨头,目前股息收益率高达6.5% [8] - 公司虽然不是高增长型,但能为投资者提供稳定的股息收益 [9] - 过去5年内,公司股息增长10%,年复合增长率约2% [10] - 即使未来增长缓慢,但凭借高股息收益,仍能为退休投资者带来可观的收益 [10] Prologis - Prologis是一家房地产投资信托公司,主要投资于仓储物流设施 [11] - 公司股息收益率为3.2%,高于平均水平 [12] - 过去5年内,公司股息增长81%,年复合增长率达12.6% [13] - 公司的核心经营指标远高于股息支付,未来有望继续大幅增加股息 [12][13]

Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future. Many of these stocks have fallen out of fashion in the tech-fueled AI revolution. But in the last month, many of these stocks are increasing as investors feel more bullish about the economy.  Investors who reinvest those dividends have the opportunity to increase their total return on th ...

All of these stocks can provide steady income to retired investors.Many retirees are investors for a good reason: They can't rely entirely on Social Security to fund their retirement. Investing wisely provides a means to retire comfortably.Three Motley Fool contributors think they have found stocks to buy that retirees should absolutely love. All three offer juicy dividend yields. Here are their cases for AbbVie (ABBV -0.25%), Bristol Myers Squibb (BMY -0.28%), and Gilead Sciences (GILD -2.55%). Everything ...